Amgen Lifts 2026 Guidance for Second Straight Quarter

Amgen raised its full-year 2026 outlook again, now projecting total revenue between $38.9 billion and $39.7 billion, up from the $38.2 billion to $39.4 billion range it gave just three months ago. The biotech also lifted its non-GAAP earnings-per-share guidance to $22.90-$23.70, compared with $22.30-$23.50 in August. $AMGN now has two consecutive quarters of upgraded targets as its growth drivers keep outpacing the company's own forecasts.